Ristova (rituximab)

This information is intended for HCP only. This is a prescription based drug. Please consult your doctor if you need more information.

Ristova was the first therapeutic monoclonal antibody to target cells that have the CD20 marker on their surface. These cells are central to many blood cancers, including common forms of lymphoma and leukaemia. Ristova attacks these cells both directly and together with the body’s immune system.

RISTOVA is a CD20-directed cytolytic antibody indicated for the treatment of:

  • Adult patients with Non-Hodgkin’s Lymphoma (NHL)

  • Pediatric patients aged 6 months and older with mature B-cell NHL and mature B-cell acute leukemia (B-AL)

  • Adult patients with Chronic Lymphocytic Leukemia (CLL)

  • Rheumatoid Arthritis (RA) in combination with methotrexate in adult patients with moderately-to severely-active RA who have inadequate response to one or more TNF antagonist therapies

  • Granulomatosis with Polyangiitis (GPA) (Wegener’s Granulomatosis) and Microscopic Polyangiitis (MPA) in adult and pediatric patients 2 years of age and older in combination with glucocorticoids

  • Moderate to severe Pemphigus Vulgaris (PV) in adult patients


This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country.Please be aware that we do not take any responsibility for accessing such information which may not comply with any valid legal process, regulation, registration or usage in the country of your origin.

ContactLocationslinkedinfacebooktwitterinstagramyoutubeAbout RochePharma solutionsStoriesRoche careersPrivacy StatementLegal Statement